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Severe burns are one of the most devastating forms of trauma.  In South Africa, burn injuries 
are the third commonest external cause of fatal injuries up to the age of 15 years and the 
main cause under the age of 4 years.  In the Cape Town region, at least six in 10 000 children 
are seriously burnt every year, and as many as 15 in 10 000 toddlers and infants. 1,2  
A number of advances have been made in recent times with regard to fluid resuscitation 
protocols, dressings, infection control strategies and antimicrobials, surgical techniques, 
intensive care and nutrition. There is now widespread recognition that specialist burns units 
or centres deliver the best care for these patients.  As a result of these measures, mortality 
and morbidity rates have declined significantly over the last few decades. 3-4 
Significant thermal injuries induce a state of immuno-suppression; three quarters of all 
severe burn related deaths are as a consequence of infection, most notably burn wound 
infections, sepsis, pneumonia and urinary tract infections, many of which are nosocomial. 4-8 
There are a number of mechanisms for the development of pneumonia in the severely 
burnt.  Pulmonary complications are common with inhalational injury, but burnt patients 
have more pulmonary complications even without direct lung injury.  Atelectasis and 
hypostatic pneumonia are common due to altered ventilation and reduced lung expansion 
that may occur in patients with chest or abdominal burns.  These patients may also have a 
high risk of aspirating, and respiratory physiotherapy with regular airway suctioning of upper 
airway secretions and expectoration of sputum may be critical to maintaining pulmonary 
function. 5,9 
Patients who require prolonged ventilation are also at risk of developing ventilator-
associated pneumonia (VAP).  Prior to 2007, VAP could only be diagnosed after 48 hours of 











diagnosis. 10   Despite this change in definition, there may still be some utility in considering 
patients in early or late groups, because causative organisms and their resistance patterns 
vary in relation to this.  
In the paediatric intensive care setting, VAP is responsible for significant morbidity and 
mortality, and ranks as the second commonest hospital acquired infection. In fact, a large 
European trial in a variety of paediatric settings showed that VAP accounted for over half of 
hospital acquired infections in the PICU. 11 
The prevalence of nosocomial pneumonia in the ICU ranges from 10 to 65% and mortality 
rates exceed 25%. Those who develop VAP are twice as likely to die compared to those 
without VAP, and spend longer in intensive care. The nosocomial bacteria that cause VAP 
tend to be more resistant. 11-15 
There is a paucity of literature on VAP in children, and particularly within the context of 
major paediatric burns.  International guidelines for the prevention and management of VAP 
have largely have been extrapolated from adult experience with VAP.   Burns patients, and 
particularly paediatric patients with burns, are a special group, with peculiar demands and 
predispositions, and should b  managed by burns surgeons, anaesthetists, specialist nursing 
staff, paediatric intensivists, physiotherapists and occupational therapists with special 
interest and experience in managing severely burnt children.     
The intention of this study will be twofold: 
1. To determine the incidence and epidemiology of VAP in this patient group in the 
setting of Red Cross War Memorial Children’s Hospital. 
2. To undertake a comprehensive literature review to determine strategies for the 
diagnosis, prevention and management of ventilator associated pneumonia in the 











2. Materials and Methods 
2.1 Study Setting  
Red Cross War Memorial Children’s Hospital (RXH) is a 288-bed state teaching hospital with 
tertiary and regional functions.  It is predominantly a referral hospital but also houses 24-
hour trauma and emergency units, both with overnight inpatient beds.  It is the only 
paediatric inpatient facility for the central health districts of Cape Town.  Its tertiary services, 
including an intensive care unit (PICU), receive referrals from southern, central and western 
parts of Cape Town, the southern half of the western Cape, other tertiary children’s services 
in the province and other provinces and other African states.  It serves children less than 13 
years of age, the vast majority of whom are dependent on state services.  Approximately 
156 000 children attend the outpatient and emergency services each year, of whom about 
18 000 are admitted.  
The RXH has the largest dedicated paediatric burns centre in South Africa with 26 beds, 
admitting more than 1000 patients annually.  The adjacent Paediatric ICU is a 30-bed facility.  
It is a combined medical and surgical ICU with specialist consultant intensivists and registrars 
with paediatrics, anaesthetics, emergency medicine and surgical backgrounds.  Burns 
patients are admitted to the ICU only if they require ventilation, at the discretion of the 
admitting surgeon in consultation with the resident ICU staff and consultants. 
2.2 Inclusion Criteria 
Patients admitted with burn injuries who required ventilation in the Paediatric ICU at Red 
Cross War Memorial Children’s Hospital (RXH) will be included in the study.  The medical 












2.3 Exclusion Criteria 
The following patients will be excluded: 
1. Patients ventilated for less than 48 hours. 
2. Patients with incomplete notes 
2.4 Study design 
Patient data was obtained by review of patient records (demographics, clinical course) and 
laboratory data (chemistry, haematology, microbiology) from the hospital database. 
The following criteria were recorded and analysed: 
1. Demographic details 
2. Aetiology of burn injury 
3. Size of burn 
4. Presence of inhalational injury 
5. Incidence of pneumonia 
6. Incidence of VAP (as diagnosed by the clinical team, irrespective of the method of 
diagnosis) 
7. Microbiology of specimens collection 
8. Method of specimen collection 
9. Length of mechanical ventilation 
10. Length of ICU stay 
11. Mortality rate 
12. Blood Transfusions 
13. Re-intubations 











Data will be recorded on a proforma designed using an Excel spreadsheet.  Data will be 
collected in the form of categoric and continuous variables, and analysed where 
appropriate. The relationship between interventions and end-points will be evaluated.  
Descriptive statistics will used throughout.  Significance is regarded as a p value of 0.05 using 
the student’s t-test.  
2.5 Patient Management 
The Parkland Formula is applied to the resuscitation of all major burns victims.  Enteral 
resuscitation and nutritional support is initiated as soon as possible. ICU admission is 
determined by the attending ICU registrar and consultant, and management within the unit 
based upon established, evidence-based protocols where available.  For instance, a 
guideline for the diagnosis, prevention and treatment of paediatric ventilator-associated 
pneumonia was published in the SAMJ in April 2009.  The South African Burns Society also 
publishes recommendations to guide the burns care professionals. 3.9  Standard burns 
management principles are practised in the unit, and early burn excision and grafting are 
adhered to as far as possible.     Patients are managed with modern closed wound dressings 
and coverage strategies, including silver based products (Acticoat16 and Aquacel Ag), and 
skin substitutes (Biobrane17 and Suprathel) when indicated.  The unit is currently setting up a 
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Major burns victims are particularly susceptible to pneumonia, especially ventilator-
associated pneumonia (VAP).  VAP remains a prominent cause of morbidity and mortality, 
despite improvements in intensive care and burns surgery in recent times.  Length of 
ventilation, type and size of burn (especially inhalational burns) are related to the incidence 
of VAP.  Other risk factors (number of re-intubations, theatre visits) are also important. 
Effective preventative strategies should be adhered to, and protocols should be 
implemented to aid in the diagnosis and treatment of VAP.  Clinical criteria, radiology, and 
broncho-alveolar lavage should be used to determine the causative organism, and there 
should be a low threshold for the early initiation of empiric therapy, based on the prevailing 
resistance patterns in the unit.  Major burns should be managed in centres where there is 






















Severe burns are one of the most devastating forms of trauma.  In South Africa, burn injuries 
are the third commonest external cause of fatal injuries up to the age of 15 years and the 
main cause under the age of 4 years.  In the Cape Town region, at least six in 10 000 children 
are seriously burnt every year, and as many as 15 in 10 000 toddlers and infants. 1,2  
A number of advances have been made in recent times with regard to fluid resuscitation 
protocols, dressings, infection control strategies and antimicrobials, surgical techniques, 
intensive care and nutrition. There is now widespread recognition that specialist burns units 
or centres deliver the best care for these patients.  As a result of these measures, mortality 
and morbidity rates have declined significantly over the last few decades. 3-4 
Significant thermal injuries induce a state of immuno-suppression; three quarters of all 
severe burn related deaths are as a consequence of infection, most notably burn wound 
infections, sepsis, pneumonia and urinary tract infections, many of which are nosocomial. 4-8  
There are a number of mechanisms for the development of pneumonia in the severely 
burnt.  Pulmonary complications are common with inhalational injury, but burnt patients 
have more pulmonary complications even without direct lung injury.  Atelectasis and 
hypostatic pneumonia are common due to altered ventilation and reduced lung expansion 
that may occur in patients with chest or abdominal burns.  These patients may also have a 
high risk of aspirating, and respiratory physiotherapy with regular airway suctioning of upper 
airway secretions and expectoration of sputum may be critical to maintaining pulmonary 
function. 5,9 
Patients who require prolonged ventilation are also at risk of developing Ventilator-
Associated Pneumonia (VAP).  Prior to 2007, VAP could only be diagnosed after 48 hours of 
mechanical ventilation.  No minimum time of ventilation is now required to make the 











patients in early or late groups, because causative organisms and their resistance patterns 
vary in relation to this.  
In the paediatric intensive care setting, VAP is responsible for significant morbidity and 
mortality, and ranks as the second commonest hospital acquired infection. In fact, a large 
European trial in a variety of paediatric settings showed that VAP accounted for over half of 
hospital acquired infections in the PICU. 11  The prevalence of nosocomial pneumonia in the 
ICU ranges from 10 to 65% and mortality rates exceed 25%. Those who develop VAP are 
twice as likely to die compared to those without VAP, and spend longer in intensive care. 
The nosocomial bacteria that cause VAP tend to be more resistant. 11-15 
There is a paucity of literature on VAP in children, and particularly within the context of 
major paediatric burns.  International guidelines for the prevention and management of VAP 
have largely been extrapolated from adult experience with VAP.   Burns patients, and 
particularly paediatric patients with burns, are a special group, with peculiar demands and 
predispositions, and should be managed by burns surgeons, anaesthetists, specialist nursing 
staff, paediatric intensivists, physiotherapists and occupational therapists with special 



















Much has been written in the critical care literature about the prominent role that VAP plays 
in respect of mortality and morbidity in the ICU.  Burns victims have the highest relative risk 
of any category of ventilated patients.  Several studies have demonstrated that the 
incidence of VAP in burns patients is more than 22 per 1000 ventilator days, more than 
double that seen in either surgical or medical cohorts.  The rate in our paediatric unit is as 
high as 30 per 1000 ventilator days. 5-8  VAP usually results from pathogens colonizing the 
lower respiratory tract and parenchyma by sustained micro aspiration.  A number of factors 
in the burns patient facilitate the development of pneumonia.  (Table 1) 
Strategies to prevent VAP in burns patients have largely been adapted from studies focusing 
on other patient groups.  Many of these have been incorporated into so-called ‘care 
bundles’ for ventilated patients.  Table 2 lists some of the preventative strategies.   
Daily interruptions and weaning protocols are now fundamental tenets of good adult ICU 
care.  The role in children is less well established, but the principal of reducing ventilation 
duration to shortest possible is obviously paramount. 9,11,16   Adaptations to the endotracheal 
tube have been examined in an attempt to reduce the incidence of VAP. The NASCENT trial, 
for instance, showed a 35.9% risk reduction when a silver impregnated endotracheal tube 
was used. 17 Techniques to continuously aspirate subglottic secretions have been shown to 
be effective and should be implemented. 17,18 At present intermittent open suctioning 
techniques are the norm in ICU’s in developing countries. 
Stress ulcer prophylaxis and early enteral nutrition are now well-established in both burns 
care and in the ICU scenario.  However, they may also be responsible for raising the pH and 
gastric bacterial colonization, which predisposes to VAP.  Gastritis is rare in the well-
resuscitated child burn victim and many units may choose not to make use of stress ulcer 











In addition, postpyloric feeding rather than gastric feeding, may reduce the incidence of 
VAP. 9, 19  Placing the patient in the semi-recumbent position is effective and easily applied in 
the adult patient, but may prove difficult in the paediatric population where there may be 
marked size differences between patients. 9 
Meta-analyses have showed a significant reduction in the incidence of pneumonia with the 
use of selective decontamination of the GIT. 20,21 Prophylactic antibiotics may also be 
justified in certain circumstances, but applied with an awareness of the prevailing resistance 
patterns. 22 Chlorhexidine mouthwash is a cost-effective and easily applied strategy for 
reducing VAP. 23, 24 Contact precautions and hand hygiene are now well-established tenets of 
critical care, and adherence to these and other elements in the ventilator care bundles need 
to be regularly reviewed. 25 
Burns patients frequently require blood transfusions during their course of treatment. A 
restrictive policy should be adhered to, as each unit of blood received is associated with a 
13% increased risk of infection, presumably by exacerbating the state of 
immunosuppression. 26,27  Intense insulin therapy and tight glucose control, despite initial 
optimism, needs to be re-evaluated in a major trial, and particularly in major paediatric 
burns.  The consequences of hypoglycaemia are potentially catastrophic, and more 

















VAP remains one of the greatest challenges to the ICU clinician.  This difficulty is illustrated 
by the fact that VAP represents the dominant indication for empiric antibiotic agents in the 
ICU.  Scoring systems like the CPIS and the CDC criteria have been compiled to improve the 
accuracy by combining clinical, microbiological and radiological criteria.  Scores of more than 
six are regarded as diagnostic. (Table 3) 30-33 
Scoring systems, however, have not been validated in paediatric burns victims, and a 
number of problems have been identified.  For instance, the burn patient frequently exhibits 
pulmonary dysfunction due to inhalational injury, overwhelming systemic inflammation, 
pulmonary oedema and ARDS.  Fever, sputum, leukocytosis or leukopaenia, deranged 
oxygenation, and abnormal chest radiographs may all be present in a burns patient without 
pneumonia. 6,9, 30-34 
The traditional 48 hours of ventilation required to make the diagnosis has now been 
removed from the definition of VAP. 10 The ventilator is recognized as a major risk factor for 
the development of pneumonia in the ICU. The spectrum of bacteria responsible 
(community acquired vs nosocomial) and the efficacy of preventative and therapeutic 
measures, make time an important component.  VAP is a prominent cause of morbidity and 
mortality in burns patients, but patients who developed pneumonia prior to 48 hours of 
ventilation were also at high risk, particularly if they had large body surface burn wounds.  
Of the organisms responsible for VAP, Acinetobacter baumanii infections, in particular, have 
proved to be a virulent cause of ventilator associated pneumonia in our setting. 6,9,11  
bronchoalveolar lavage, Protected specimen brush or non-bronchoscopic lavage are the best 
means of obtaining reliable quantitative cultures.  By combining one of these techniques 
with clinical features of pulmonary infection, the sensitivity and specificity may be 












Several studies have demonstrated that a delay in initiating appropriate antibiotics may 
result in increased morbidity and mortality.  Consequently units should be aware of their 
local bacterial milieu and resistance patterns, so that appropriate empiric antibiotics choices 
can be made. 6,9,11,37 Pneumonias that occur early are more likely community acquired, most 
notably Streptococcus pneumoniae and Haemophilus influenzae.  Later onset VAP’s are more 
likely a consequence of MRSA and gram negative organisms like Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella pneumonia, Acinetobacter baumanii. 6 
Pseudomonas aeruginosa remains the most invasive pathogen in our patients, but 
Acinetobacter baumanii is now also a major problem, not least because of growing 
resistance.   Methicillin-resistant Staphylococcus aureus has not yet proved as significant a 
problem as experienced in other parts of the world.  Because many of our patients are 
immunocompromised and malnourished prior to burn injury, several of our patients are 
particularly susceptible to fungal infections.   
Many ICU’s are still dependent on alternatives to invasive quantitative microbiological 
techniques like sputum cultures and tracheal aspirates.  The results of these tests are 
relatively unreliable and treatment should be initiated and de-escalated with this is mind.  If 
possible, empiric therapy should be limited to 48 hours: this period of use should not 
increase resistance. 38, 39 Antibiotics may safely be stopped once clinical features of infection 
have resolved.  There is probably no difference in outcomes if an eight or fifteen day course 
of treatment is implemented, unless the organism responsible is Pseudomonas aeruginosa 
or Acinetobacter, where a longer course is necessary to reduce recurrence. 39   Table 4 lists 














1. Intubation (especially pre-
hospital/ emergency) 
Bypass glottis barrier; pooling, leak of and inability to 
clear secretions 
2. Cutaneous thermal injury Bacterial Reservoir; systemic inflammation; 
immunosuppression 
3. Prolonged ventilation Sustained micro-aspiration; secretions; reintubation 
4. Inhalational injury Direct injury; exudate formation; poor mucociliary 
clearance; reduced lung compliance; ARDS; 
prolonged ventilation; 
5. Transport out of ICU (e.g. 
theatre) 
Reintubation; bacterial translocation 
6. Blood transfusions Immunosuppression 
Table 1.  Factors predisposing the burns patient to pneumonia in ICU 
Preventative Strategies 
1. Reduce the duration of ventilation 
2. Postpyloric feeding 
3. Chlorhexidine mouth wash 
4. Reduce transfusions 
5. Head elevation 
6. Selective decontamination of the GIT 
7. Staff factors – hand hygiene and barrier 
nursing 
8. Silver endotracheal tubes and continuous 
aspiration 
















 0 1 2 
Leukocytes (109/l) 4 - 11 <4 >11 
Tracheal Secretions Absent Non-purulent Purulent 
Oxygenation 
(PaO2/FiO2) 
>240  <240 




Tracheal Aspirate <103 103 – 1003 >1003 
Temperature 36.1 – 38.4 38.4 – 38.9 >39; <36 
Table 3. The Clinical Pulmonary Infection Score 
Principles of therapy  
1. Empiric antibiotics Initiate early 
 Broad spectrum 
 New agent for patient 
2. De-escalation Preferably within 48 hours 
 Adjust according to culture and sensitivity   
 Monotherapy preferably 
 Consider Linezolid as alternative to vancomycin for MRSA 
 Consider coliston for carbapenam resistant Acinetobacter species 
 Consider using aerosolized agents 
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More than three-quarters of deaths related to major burns are a consequence of infection, 
most notably pneumonia.  A retrospective study was performed of children (under 13 years 
of age) with major burn injuries who were ventilated during their course of treatment, over 
a five-year period. 
92 patients were included in the study; their mean age was 3.5 years and their mean total 
body surface area burn was 30%.  62% of the patients sustained flame burns, and 31% 
scalds. The mean ICU stay was 10.6 days (range 2-61 days) and the mean ventilation time 
was 8.4 days (range 2-45 days.  There were 59 documented episodes of pneumonia in 52 
patients with a rate of 30 infections per 1000 ventilator days.  Length of ventilation and the 
presence of inhalational injury correlate with the incidence of.  Chest X-Ray remains the 
single most important factor used to diagnose pneumonia in the ICU, although organism 
culture, change in ventilatory requirements and clinical examination remain important.  This 
unit has since validated the use of the Clinical Pulmonary Infection Score to aid in the 
diagnosis of VAP.  17.4 % of the patients died (n=16); half of these deaths may be attributed 
directly to pneumonia.  
Streptococcus pneumonia, Pseudomonas aeruginosa, Acinetobacter baumanii and 
Staphylococcus aureus were the most prominent aetiological organisms; Pseudomonas 
aeruginosa and Acinetobacter baumanii were the leading causes of ventilator- associated 
pneumonia.  Most of the organisms were identified by tracheal aspirate, although broncho-
alveolar lavage was found to be more specific and sensitive at identifying the organism 
deemed responsible.    
This study highlights the importance of implementing strictly enforced strategies for the 












Severe burns are one of the most devastating forms of trauma.  In South Africa, burn injuries 
are the third commonest external cause of fatal injuries up to the age of 18 years and the 
main cause under the age of 4 years.  In the Cape Town region, at least six in 10 000 children 
are seriously burnt every year, and as many as 15 in 10 000 toddlers and infants. 1,2  
The modern treatment of burns has become a logical exercise in resuscitation, infection 
control, surgical wound care, pain relief, nutrition and psychological and physical 
rehabilitation. These methods are aided by technological advances in biological and 
synthetic skin substitutes, pharmacological amelioration of the hyper-metabolic response, 
and physical exercise programs. There is now widespread recognition that specialist burns 
units or centres deliver the best care for these patients.  As a result of these measures, 
mortality and morbidity rates have declined significantly over the last few decades. 3-4 
Significant thermal injuries induce a state of immuno-suppression; three quarters of all 
severe burn related deaths are as a consequence of infection, most notably burn wound 
infections, sepsis, pneumonia and urinary tract infections, many of which are nosocomial. 4-8 
Pulmonary complications are common with inhalational injury, but burnt patients have more 
pulmonary complications even without direct lung injury.  There are a number of 
mechanisms for the development of pneumonia in the severely burnt.  Atelectasis and 
hypostatic pneumonia are common due to altered ventilation and reduced lung expansion 
that may occur in patients with chest or abdominal burns.  These patients may also have a 
high risk of aspirating, and respiratory physiotherapy with regular airway suctioning of upper 












Patients who require prolonged ventilation are also at risk of developing ventilator-
associated pneumonia (VAP), which is a nosocomial lower respiratory tract infection in 
ventilated patients.  Prior to 2007, VAP could only be diagnosed after 48 hours of 
mechanical ventilation, but no minimum time of ventilation is now required to make the 
diagnosis. 5,10   Despite this change in definition, there may still be some utility in considering 
patients in early or late groups, because causative organisms and their resistance patterns 
vary in relation to this.  
In the paediatric intensive care setting, VAP is responsible for significant morbidity and 
mortality, and ranks as the second commonest hospital acquired infectio . In fact, a large 
European trial in a variety of paediatric settings showed that VAP accounted for over half of 
hospital-acquired infections in the PICU. 11  The prevalence of nosocomial pneumonia in the 
ICU ranges from 10 to 65% and mortality rates exceed 25%. Those who develop VAP are 
twice as likely to die compared to those without VAP, and spend longer in intensive care. 
The nosocomial bacteria that cause VAP tend to be more resistant. 7,8,11 
The application of preventative intensive care bundles has been paramount in reductions in 
VAP noted in this ICU over recent years.  The timely diagnosis and treatment of VAP is 
critically important to lim t significant morbidity and mortality. 12 
There is a paucity of literature on VAP in children, and particularly within the context of 
major paediatric burns.  International guidelines for the prevention and management of VAP 
have largely been extrapolated from adult experience with VAP.   Burns patients, and 
particularly paediatric patients with burns, are a special group, with peculiar demands and 
predispositions, and should be managed by burns surgeons, anaesthetists, specialist nursing 
staff, paediatric intensivists, physiotherapists and occupational therapists with special 
interest and experience in managing severely burnt children.     











1. To describe the incidence and epidemiology of ventilator-associated pneumonia 
(VAP) in this patient group in the setting of Red Cross War Memorial Children’s 
Hospital. 
2. To undertake a comprehensive literature review to determine strategies for the 
cost-effective diagnosis, prevention and management of ventilator associated 

























2. Materials and Methods 
The RXH is a 288-bed state teaching hospital with tertiary and regional functions.  It is 
predominantly a referral hospital but also houses 24-hour trauma and emergency units, 
both with overnight inpatient beds.  It is the only paediatric inpatient facility for the central 
health districts of Cape Town.  Its tertiary services, including an intensive care unit (PICU), 
receive referrals from southern, central and western parts of Cape Town, the southern half 
of the western Cape, other tertiary children’s services in the province, other provinces, as 
well as other African states.  It serves children under 13 years of age, the vast majority of 
whom are dependent on state services.  Approximately 156 000 children attend the 
outpatient and emergency services each year, of whom about 18 000 are admitted.  
The RXH has the largest dedicated paediatric burns centre in South Africa with 18 beds, 
admitting more than 1000 patients annually.  The adjacent Paediatric ICU is a 20-bed facility.  
It is a combined medical and surgical ICU with specialist consultant intensivists and registrars 
with paediatrics, anaesthetics, emergency medicine and surgical backgrounds.  Burns 
patients are admitted to the ICU if they require ventilation, at the discretion of the admitting 
surgeon in consultation with the resident ICU staff and consultants.  
Patients admitted with burn injuries who required ventilation in the Paediatric ICU at Red 
Cross War Memorial Children’s Hospital (RXH) were included in the study.  The medical 
records were collected from a five-year period (January 2005 to December 2009).  Patients 
were excluded from study if they had incomplete notes, or were ventilated for less than 48 
hours. 
Patient data was obtained by review of patient records (demographics, clinical course) and 
laboratory data (chemistry, haematology, microbiology) from the hospital database. The 
following criteria were recorded and analysed: demographic details, aetiology of burn injury, 











diagnosis as per the medical records, irrespective of the method diagnosis), microbiology of 
specimens’ collection, method of specimen collection, length of mechanical ventilation, 
length of ICU stay and mortality.  
Standard protocols were used during the emergency and acute phases of treatment, 
including the Parkland formula for fluid resuscitation, escharotomy if needed, early enteral 
nutritional support, topical wound care, early burn excision and grafting, and pain control. 
The South African Burn Society also publishes recommendations to guide burns care 
professionals. 3.4 Patients are managed with modern closed wound dressings and coverage 
strategies, including silver based products (Acticoat13 and Aquacel Ag), and skin substitutes 
(Biobrane14 and Suprathel) when indicated.  The unit is currently setting up a deceased 
donor allograft skin bank to improve access to cadaver skin. 
ICU admission was determined by the attending ICU registrar and consultant, and 
management within the unit was based on care bundles and established, evidence-based 
protocols9. Criteria for admission include: major burns exceeding 30% TBSA (total body 
surface area), extensive facial and neck burns (especially in small children), suspected or 
confirmed smoke or hot liquid inhalation, significant carbon monoxide poisoning, physical 
evidence of upper airway burns, potential for airway obstruction, high voltage electrical 
burns, depressed level of consciousness and hypoxic brain injury.  
The clinical diagnosis of Ventilation Association Pneumonia (VAP) was based on published 
guidelines utilised by the ICU staff prior to 2010 and supplemented by additional criteria.15,16 
Criteria used included: new and persistent radiographic evidence of focal infiltrates 48 hours 
or more after introducing mechanical ventilation; changes in ventilator or oxygenation 
parameters; the development of hypo- or hyperthermia; changes in white cell counts; 
cough; changes in chest signs; changes in the nature of endotracheal secretions and 











 Prior to 2007, VAP could only be diagnosed after 48 hours of mechanical ventilation.  No 
minimum time of ventilation is now required to make the diagnosis. 11  Despite this change in 
definition, there may still be some utility in considering patients in early or late groups, 
because causative organisms and their resistance patterns vary in relation to this.   For the 
purposes of this study, conducted in part prior to the changes, the old definition is applied. 
Data were recorded on a proforma and then transferred to Excel (Microsoft Excel 2008 for 
Mac Version 12.3.0).  Data were collected in the form of categoric and continuous variables, 
and analysed where appropriate using Epi-info (http://www.cdc.gov/epiinfo).  The 
relationship between interventions and end-points were evaluated.  Descriptive statistics 
are used throughout. Significance is regarded as a p value of <0.05 using the student’s t-test. 
Institutional and departmental approval was obtained to complete the study.  The project 
number assigned by the Department of Surgery Research Committee was 2013/055, and by 





















Over a five-year period (January 2005 to December 2009), 108 patients were admitted to 
the RXH Paediatric ICU with burn injuries.  Sixteen patients were excluded from further 
study on the basis of either inadequate or incomplete records (n=5) or because the patient 
was ventilated for a period shorter than 48 hours (n=11).   
The mean patient age was 3.5 years (range 4 months to 13 years, median 1.67 years).  59 % 
(n=54) of the patients were male and 41% (n=38) were female.  The mean percentage total 
body surface area (TBSA) burnt was 30% (median 26%, range 3-90%).  72% of the patients (n 
= 66) had areas of full thickness burns.  
Scald and flame burns were the commonest mechanisms of injury.  63% (n=58) of the 
patients sustained flame burns, 33% (n=30) scalds and 4 sustained other kinds of burns 
(contact, electrical or chemical). Twenty patients had documented evidence of inhalational 
burns (22% of the total group, 32% of the flame burn group).   
Scald injuries occurred most commonly in the very young, with a mean age of 1.63 years 
(range 0.3-9 years), whereas the mean age of those who sustained flame burns was 5.12 
years (range 0.25 – 13 years).   
53 % (n=49) of the patients were admitted to the PICU within 12 hours of the injury.  
Patients who sustained flame burns were far more likely to be admitted early in their clinical 
course, with 57% (n=33) admitted in the first 12 hours and 84% (n=49) within the first 24 
hours. Only 7% (n=4) of flame burnt children were admitted for the first time after 48 hours.  
As many as 36% (n=11) of scalds are only admitted to the PICU for the first time between 48 
hours and one week after the injury.  
57% (n=52) of the patients were diagnosed and treated for at least one episode of 











episodes (in 37 patients) met the criteria for ventilator-associated pneumonia (VAP). 18 of 
the episodes (in 15 patients) did not meet the unit’s criteria for VAP, usually because they 
had manifested clinical features of pneumonia prior to 48 hours of ventilation (as per the 
previous definition of VAP). The rate of VAP was 30 infections per 1000 ventilator days.  The 
average TBSA of patients who developed VAP was 31%, not significantly different from the 
rest of the group.  43% of the patients (n=40), despite being ventilated, did not develop 
pneumonia. 
The mean number of re-intubations was 1.47 per patient (range 0-6). The mean ICU stay was 
10.6 days (range 2-61 days), 14 days for those who died (range 2-46 days), and 15.4 days for 
those with VAP. The mean ventilation time was 8.4 days. (range 2 – 31 days, median 9 days).  
The mean number of ventilation days was at least three days longer in those with VAP 
compared to those without.  The mean number of theatre visits was 5 (range 2 – 19).  
Length of ICU stay correlated with a significantly increased incidence of VAP (p<0.05).  
Selected results are compared between those with and those without VAP in Figure 1. 
The investigative modality deemed most important when deciding to initiate antibiotics for 
pneumonia (as documented in the patient records) was chest x-ray findings (34%), organism 
culture (27%) and clinical examination (39%).  The CPIS was inconsistently recorded during 
this period.  
75 organisms were cultured and deemed responsible for pneumonia in 59 episodes in 52 
patients during their stay in ICU.  Broncho-alveolar lavage (BAL) identified the responsible 
organism in 16 of the 59 pneumonias, tracheal aspirates (34) and sputum the remainder.  
Antibiotics were more likely to be adjusted according to the BAL result than the alternative 
methods.  Quantitative sampling and further clinical correlation were utilized in the cases of 











Streptococcus pneumoniae was the aetiological organism in 18 cases.  Other important 
organisms in the whole group included Pseudomonas aeruginosea, Acinetobacter baumannii 
and Staphylococcus aureus.  VAP was caused by Acinetobacter baumannii in 13 cases.  
Pseudomonas aeruginosa (n=9), Staphylococcus aureus (n=9) and Streptococcus pneumonia 
(n=7) were other prominent aetiological organisms.  In two patients with VAP, viruses were 
responsible. 
The other pneumonias (i.e. the group not classified as VAP) were caused by Streptococcus 
pneumoniae (n=13), Haemophilus influenzae (n=7), Pseudomonas aeruginosa (n=5), 
Klebsiella pneumoniae (n=4) and Moraxella catarrhalis (n=4). Acinetobacter baumannii was 
only cultured in one of these cases.  Streptococcus pneumoniae infection was commonly 
associated with culture of other organisms such as Moraxella catarrhalis and Haemophilus 
influenzae.  There was one case of Tuberculosis and two cases of viral pneumonias in this 
category.  These cases were more likely to yield polymicrobial organisms. Figure 2 is a 
summary of prominent organisms in each category.  
There is a significant degree of resistance in the PICU setting; Both Acinetobacter baumannii 
and Klebsiella pneumonia demonstrate extended spectrum beta lactamase production in 
excess of 20%, and Pseudomonas aeruginosa cultured demonstrates a similar degree of 
carbapenam resistance.  
Most patients (n=54, 91.5%) were receiving empiric intravenous antibiotics prior to 
organism identification.  Bloodstream infections (positive blood cultures) were documented 
in 31 patients, with 43 organisms.  In 9 cases (15%) of pneumonia the organism (with a 
similar sensitivity profile) was also cultured from the burn wound; most frequently this 
organism was Pseudomonas aeruginosa.  In 16 episodes (27%) the causative organism was 












17.4% (n=16) of the patients died.  63% (n=10) of those who died had sustained flame burns, 
whereas 25% (n=4)  had sustained scalds and one each had electrical and chemical burns.  
The average TBSA of those who died was 46.8% (range 8 -90%, median 35%), significantly 
different from the mean TBSA of the whole group, which was 30% (range 3-90 %, median 
26%) (p<0.05). 
Half (n=8) of the deaths can be attributed to pneumonia. Six of these patients had VAP 
(causative organisms were Klebsiella pneumoniae in one case and Acinetobacter baumanii in 
three cases).  Seven of the patients died of overwhelming Pseudomonas aeruginosa sepsis.  
Multiorgan dysfunction and head trauma comprised the remaining causes of death.  One 
patient manifested features of fluid creep, and required laparotomy for abdominal 























Many of the severely burnt children who are admitted to hospital and die, will die in the 
intensive care setting of complications of either burn wound infections or pneumonia. There 
is a notable absence of literature related to VAP in the paediatric burns setting, especially 
from the developing world, despite the recognition that burns is a significant independent 
risk factor for VAP. 6,7 
Nevertheless, much has been written in the critical care literature about the prominent role 
that VAP plays in respect of mortality and morbidity in the ICU.  Burns victims have the 
highest relative risk of any category of ventilated patients.  Several studies have 
demonstrated that the incidence of VAP in burns patients is more than 22 per 1000 
ventilator days, more than double that seen in either surgical or medical cohorts.  The rate in 
this study was 30 episodes per 1000 ventilator days, which would be in keeping with the 
literature. 5-8 
VAP usually results from pathogens colonizing the lower respiratory tract and parenchyma 
by sustained micro aspiration, and less commonly from haematogenous spread of infection. 
Burnt patients have a number of specific risk factors for developing VAP including the 
detrimental systemic effects and contamination of the burn wound itself, inhalation injury, 
as well as the prolonged mechanical ventilation and ICU stay. 
 The diagnosis of VAP remains one of the greatest challenges to the PICU clinician, but 
especially in the burnt patient where systemic inflammatory responses and lung injury are 
prevalent. Although there are a number of proposed definitions, we have adopted for this 
study a clinical diagnosis of a nosocomial lower respiratory tract infection which occurs in 
mechanically ventilated patients 48 hours or more after initiating ventilator support, 











Scoring systems like the Clinical Pulmonary Infection Score (CPIS) have been compiled to 
improve the accuracy by combining clinical, microbiological and radiological criteria.  Scores 
of more than six are regarded as diagnostic. (Figure 3) 16-18 The CPIS has recently been 
validated at this hospital in the general pediatric ICU population and every ventilated patient 
is now allocated a score on a daily basis. This has resulted in a significant reduction in the 
incidence of VAP. 12 
 Scoring systems have not been validated in the pediatric burns victims; a number of 
problems have been identified with their application in this context. The burn patient 
frequently exhibits pulmonary dysfunction due to inhalational injury, overwhelming 
systemic inflammatory response, pulmonary oedema and ARDS.  Fever, sputum, 
leukocytosis or leukopaenia, deranged oxygenation, and abnormal chest radiographs may 
also all be present in a burns patient without pneumonia 5-7 
VAP is a prominent cause of morbidity and mortality in our burnt patients, but can be 
preceded by prior lung pathology. Fourteen of the cohort had evidence of pneumonia prior 
to 48 hours. These patients are also at high risk, particularly if they had large body surface 
burn wounds.  To accommodate this frequent scenario, the traditional definition of 48 hours 
required for the diagnosis of VAP, has been revised.  The latest guidelines state that there is 
no minimum period.  This takes into account contributing factors such as inhalation injury, 
pre-hospital and emergency intubation, pre-excising reactive airway disease, the different  
spectrum of bacteria responsible (community acquired versus nosocomial) and  the efficacy 
of preventative and therapeutic measures.   Of the organisms responsible for VAP, 
Acinetobacter baumanii infections, in particular, have proved to be a virulent cause of VAP 
in our setting.  
 Establishing the diagnosis of VAP in a burnt patient can be difficult and the presence of the 











contribute to the diagnostic dilemma.18  Bronchoalveolar lavage, protected specimen brush 
or non-bronchoscopic lavage are the best means of obtaining reliable quantitative cultures. 
By combining one of these techniques with clinical features of pulmonary infection, the 
sensitivity and specificity may be optimized. 6,9,11  
Strategies to prevent VAP in burns patients have largely been adapted from studies focusing 
on other patient groups.  Many of these have been incorporated into so-called ‘care 
bundles’ for ventilated patients.  
Daily interruptions of sedation and daily spontaneous breathing trials may facilitate early 
extubation.5 Its role in children is less well established, but the principal of reducing 
ventilation duration to shortest possible is obviously paramount. The reason for intubation 
was seldom formally documented, but in our setting it was frequently related to the 
magnitude of the burn, significant and progressive facial and or cervical swelling, 
inhalational injury below the larynx and deterioration of airway patency. The latter was 
based on history and clinical findings and corroborated through direct vision or fibre-optic 
laryngoscopy. 
There is insufficient data to support either oral or nasal intubation methods in paediatric 
practice although oro-tracheal tubes are more prone to accidental extubation.9   Adaptations 
to the endotracheal tube have been examined in an attempt to reduce the incidence of VAP. 
The NASCENT trial showed a 40% risk reduction when silver impregnated endotracheal tube 
was used.19  Techniques to continuously aspirate subglottic secretions have been shown to 
be effective in adults, but are not verified in children, and therefore are not applied in this 
unit9,20  
 Noninvasive ventilatory (NIPPV) strategies are being utilised with increasing efficacy.  This is 
unlikely to be appropriate for most severely burnt children requiring ventilator support 











endotracheal intubation and ventilation must be considered whenever possible.  The 
principles of non-invasive ventilation are outlined in appendix 3.  Recently, NIPPV helmets 
have been designed for this purpose and may be applied in older children. 21 
Stress ulcer prophylaxis and early enteral nutrition are now well-established in both burns 
care and in the ICU scenario.  Gastritis is rare in the well-resuscitated child burn victim and  
stress ulcer prophylaxis should not be routinely used as data to support its use is lacking.9    
In addition, postpyloric feeding rather than gastric feeding may reduce the incidence of 
VAP.9  Whenever possible, it is the practice of this unit to place a nasojejenal tube for early 
enteral feeding during the process of resuscitation.  There have been a number of benefits 
to this strategy, not least in the perioperative period, when physiological feeding methods 
may be continued despite pending theatre visits and procedures. Placing the patient in the 
semi-recumbent position is effective and easily applied in the adult, but may prove difficult 
in the paediatric population where there may be marked size differences between patients.  
Wedge shaped mattresses of various sizes and objects placed under the legs of the bed have 
been inconsistently applied.  9 
Meta-analyses have showed a significant reduction in the incidence of pneumonia with the 
use of selective decontamination of the GIT in adults. 22,23 The routine use of prophylactic 
antibiotics should be discouraged  in children,  especially  in the context of  high levels of 
antibiotic resistance.  
Chlorhexidine mouthwash has been a routine, easily applied and cost-effective strategy for 
reducing VAP. 24,25  Contact precautions and hand hygiene are now well-established tenets of 
critical care, and adherence to these and other elements in the ventilator care bundles need 
to be regularly reviewed.26 With the open structure of our paediatric ICU, the regular use of 
alcohol based hand wash, gloves and aprons have been important simple measures to 











important, but may be more difficult to apply in resource restricted settings.  The care 
bundles introduced in the ICU and applied to all children with burns consist of: elevating the 
head of bed, oral hygiene, limiting sedation, early weaning and extubation, correct 
positioning of ventilation and enteral tubing and the avoidance of saline use during 
suctioning.  
Burns patients frequently require blood transfusions during their course of treatment. A 
restrictive policy should be adhered to, as each unit of blood received has been associated 
with a 13% increased risk of infection, presumably by exacerbating the state of 
immunosuppression. 27,28 Prior to major surgery, we transfuse our patients to a Haemoglobin 
of 10g%, and make regular use of packed cells for transfusion, and adrenaline-containing 
solutions for infiltration (‘clysis’) during surgery.   
Intense insulin therapy and tight glucose control, despite initial optimism, needs to be re-
evaluated in a major trial, and particularly in major paediatric burns.  The consequences of 
hypoglycaemia are potentially catastrophic, and more significant than the potentiation of 
infection during periods of high normoglycaemia, or even hyperglycaemia. 29,30 
Probiotics have been identifi d as a potentially useful adjunct to the VAP bundle.  Proposed 
mechanisms have included: to increase mucous production and the barrier function of the 
gut; competition with pathogens for epithelial adherence; an up-regulating effect on the 
secretion of host cell antimicrobial peptides; direct pathogen killing and immunomodulation 
and induction of lymphoid cells.  There has been inconclusive evidence due to variability 
across studies with respect to probiotic strain, dosing, duration, route of administration, and 
diagnostic criteria for VAP.  As such, we require more rigorous multi-centre studies to justify 
use of this strategy at this time. 31 
Several studies have demonstrated that a delay in initiating appropriate antibiotics may 











local bacterial milieu and resistance patterns, to guide appropriate antibiotics choices. 6,9,11 
Pneumonias that occur early are more likely community acquired, most notably 
Streptococcus pneumonia and Haemophilus influenzae, and are more likely to be susceptible 
to antibiotic therapy. This is in contrast to later onset VAP’s, more likely a consequence of 
Acinetobacter baumanii, Pseudomonas aeruginosa, Staphylococcus aureus, and gram-
negative organisms (Escherichia Coli and Klebsiella pneumonia). 6    
Of great concern has been the identification of viruses contributing to the severity of VAP.  
Before April 2009, viral isolation and identification techniques were suboptimal and 
dependent on cell cultures or antigen detection. This could explain the low yield of viral 
respiratory pathogens amongst our patients in this study. In future, viral identification 
should become an integral investigation in burnt children on mechanical ventilation. 32 
We are still dependent on alternatives to invasive quantitative microbiological techniques, 
like sputum cultures and tracheal aspirates.  The results of these tests are relatively 
unreliable and treatment should be initiated and de-escalated with this is mind.  If possible, 
empiric therapy should be limited to 48 hours: this period of use should not increase 
resistance. 5,6,33,34 Antibiotics may safely be stopped once clinical features of infection have 
resolved.   
There is probably no difference in outcomes if an eight- or fifteen-day course of treatment is 
implemented, unless the organism responsible is Pseudomonas aeruginosa or Acinetobacter 
baumanii where a longer course is necessary to reduce recurrence. 35  
Figure 4 outlines a broad diagnostic and therapeutic algorithm for VAP.  
Weaknesses inherent in retrospective studies are applicable here.  In an attempt to 
eradicate bias, members of the paediatric intensive care team were not involved in the 











the medical records of the patients included, and the applicable laboratory data.  Errors and 
omissions in record keeping may not reflect the comprehensive nature of the patient’s care.   
Nevertheless, we believe that this study reflects the susceptibility of burns patients to VAP, 
as well as demographic information, highlights some of the prominent risk factors and 
emphasizes the strategies required to diagnose and manage VAP in resource-restricted 
settings.  Prospective trials are required in this setting to eradicate confounding variables to 
clearly demonstrate the efficacy of strategies used to prevent, diagnose and treat VAP in 

























Major burns victims are particularly susceptible to pneumonia, especially ventilator-
associated pneumonia.  VAP remains a prominent cause of morbidity and mortality, despite 
improvements in intensive care and burns surgery in recent times.  Length of ventilation and 
the type and size of burn (especially inhalational) correlate with the incidence of VAP.  Other 
risk factors (number of re-intubations, theatre visits) are also important. 
Effective preventative strategies should be adhered to, and protocols should be 
implemented to aid in the diagnosis and treatment of VAP.  Clinical criteria, radiology, and 
broncho-alveolar lavage should be used to determine the causative organism, and there 
should be a low threshold for the early initiation of empiric therapy, based on the prevailing 
resistance patterns in the unit.  Major burns should be managed in centres where there is 






















 Pts with VAP (n= 37) 
(41 episodes) 
Others (n = 55) Significant  
(P<0.05) 
Ventilator Days 11.2 8  * 
Length of Stay 15.4 days 7.4 days * 
Theatre Visits 6.5 5  
TBSA 31% 28%  
Mortality 8 (21.6%) 8 (14.5%) * 
 
Figure 1.  Comparison of results comparing VAP, and those not diagnosed with VAP 
 
 
Prominent organisms cultured in VAP group 
 
Prominent organisms cultured in the other 
group with pneumonia (usually early onset) 
Acinetobacter spp (13) 
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Figure 2. Prominent organisms cultured in those diagnosed with VAP, and those with 
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NIV – Non-invasive ventilation 
NIPPV - Non-Invasive Positive Pressure Ventilation 
ARDS – Acute Respiratory Distress Syndrome 
VAP – Ventilator-Associated Pneumonia 
CPAP – continuous positive airway pressure 


















Inhalational Burns, Intubation and Mechanical Ventilation 
Severe burns are one of the most devastating forms of trauma.  In South Africa, burn injuries 
are the third commonest external cause of fatal injuries up to the age of 15 years and the 
main cause under the age of 4 years.  In the Cape Town region, at least six in 10 000 children 
are seriously burnt every year, and as many as 15 in 10 000 toddlers and infants. 1-3 
While the majority of paediatric burns are scalds sustained in the domestic setting, a greater 
proportion of the adult burns, and the more severe burns in children, are flame burns.  
These are most common in informal housing as a result of the use of paraffin stoves for 
cooking and heating; other prominent causes of flame burns in adults include accidents in 
the workplace, and as a result of epilepsy or interpersonal assault.  Burn victims caught in 
enclosed spaces are frequently the most severely injured, and those who suffer smoke 
inhalation injury may have mortality rates over 30%. 4,5   
A number of advances have been made in recent times with regard to fluid resuscitation 
protocols, dressings, infection control strategies and antimicrobials, surgical techniques, 
intensive care and nutrition. There is now widespread recognition that specialist burns units 
or centres deliver the best care for these patients.  As a result of these measures, mortality 
and morbidity rates have declined significantly over the last few decades. 3, 6,7 
The main challenge to those managing major burns is now resisting the threat of 
overwhelming infection.  Because significant thermal injuries induce a state of immuno-
suppression and the wounds themselves are exposed to micro-organisms prior to skin graft 
coverage, three quarters of all severe burn related deaths are as a consequence of infection. 
Besides burn wound infections, these may manifest as sepsis and pneumonia, many of 
which are nosocomial.   There are a number of mechanisms for the development of 
pneumonia in the severely burnt. (Figure 1)  Pulmonary complications are undoubtedly 











even without direct lung injury.  Atelectasis and hypostatic pneumonia are common due to 
altered ventilation and reduced lung expansion that may occur in patients with chest or 
abdominal burns.  These patients may also have a high risk of aspirating, and respiratory 
physiotherapy with regular airway suctioning of upper airway secretions and expectoration 
of sputum may be critical to maintaining pulmonary function. 3,8,9 
The overwhelming systemic inflammation associated with a major burn may result in 
respiratory compromise itself, manifesting as Acute Respiratory Distress Syndrome (ARDS).  
Lower respiratory infection in the presence of major burn injury carries an additive mortality 
of 60%. 5 
Those who require prolonged ventilation are at risk of developing Ventilator-Associated 
Pneumonia (VAP).   VAP is responsible for significant morbidity and mortality, and ranks as 
the second commonest hospital acquired infection. In fact, a large European trial in a variety 
of paediatric settings showed that VAP accounted for over half of hospital acquired 
infections in the PICU. The prevalence of nosocomial pneumonia in the ICU ranges from 10 
to 65% and mortality rates exceed 25%. Those who develop VAP are twice as likely to die 
compared to those without VAP, and spend longer in intensive care. In addition, the 
nosocomial bacteria that cause VAP tend to be more resistant. 10 
The incidence of VAP in major burns in our setting is as high as 30 cases per 1000 ventilator 
days, more than double that in any other category of ventilated patients.  A protocol has 
been implemented to reduce the incidence of VAP: some of these preventative strategies 
are listed in Figure 2. Undoubtedly the most effective strategy of all has been to reduce the 
length of ventilation. 3 
Critical to managing patients at risk is to reduce secondary insults inherent in management 
strategies.  Endotracheal intubation and mechanical ventilation has been the mainstay of 











three-quarters of inhalational burn victims require some form of respiratory support. 11   
Other than VAP, there are significant potential complications inherent in intubation and 
mechanical ventilation.  During the process of intubation, up to 20% of patients experience a 
period of hypoxaemia, 10% are hypotensive, 7% have oesophageal intubations and 6% 
aspirate.  Other complications include dental injury or inadvertent extraction, swallowing 
dysfunction, dysphonia and tracheal stenosis.  Repetitive laryngeal barotrauma can result 
from suction catheter use for clearing secretions.  12,13 
Some authors have suggested that the features used to guide physicians have overstated 
the need for invasive ventilation, particularly in the hospital setting.  Emergency intubation 
at the scene of the fire, with its higher complication risk, should be avoided wherever 
possible.  The clinical features on history and examination, so-called soft signs (singed nasal 
hair, closed space fire and facial burns) and hard signs (stridor, hoarse voice and dysphagia), 
used to guide physicians to intubate and ventilate burn victims, may be less helpful than 
traditionally taught, in respect to their accuracy at determining the actual need for 
ventilation.  This is particularly relevant in light of the risks involved and the possibility of an 
effective alternative to invasive airway management. 12, 14 
In fire related deaths, the toxic products of combustion are probably more important a 
cause of morbidity than the airway thermal burn itself.  The effects of direct thermal burns 
in the oropharynx are analogous to those changes occurring elsewhere in the body.  Protein 
is denatured, activating the complement cascade, histamine, xanthine oxidase, and oxygen 
free radicals, which are responsible for further protein extravasation and oedema.  Toxins 
and inhaled products interfere with the normally effective methods of clearance in the 
upper airways.  In the trachea and bronchi, ciliated epithelium and mucus-secreting 
epithelium normally make up the ‘mucociliary escalator’, capable of removing inhaled 











clearance and airway obstruction. The presence of a cuffed endotracheal tube may itself 
further interfere with this mucociliary elevator. Bronchoconstriction and mucosal  sloughing 
may result in atelectasis, with possible progression to pneumonia. 12, 15, 16 
 
Non-invasive Ventilation in Major Burn Injuries 
 
The International Consensus Conference in Intensive Care Medicine17 defined NIPPV as any 
form of ventilatory support without the use of an endotracheal tube.  Its goal is to decrease 
the work of breathing, optimize ventilatory exchange and avoid intubation.  Typically, NIV is 
positive pressure ventilation with the use of a facemask attached to a ventilator.  CPAP 
masks are widely used for improving oxygenation in hypoxaemic patients and to rest 
patients with chronic disorders like COPD or neuromuscular disorders.  The benefits of 
noninvasive positive pressure ventilation (NIPPV) are most described for avoiding re-
intubation (by more than 50%) after exacerbations of COPD. As a result, mortality and 
hospital length of stay have reduced.  Recognising the benefits of NIV, clinicians have 
attempted NIV and adapted its use for managing acute reversible respiratory failure in 
addition to the traditional uses.  NIV has seldom been used in the context of burns patients, 
but it has been shown to be an effective means of oxygenating awake and alert surgical and 
injured patients. 
 
NIV’s principle benefit is obviously the avoidance of intubation and its concomitant 
complications.  There are a number of additional benefits in avoiding intubation in the burns 
patient.  Non-intubated patients maintain better oral hygiene and gut function (they may be 
able to continue with standard oral intake), critical components in the management of major 
burn victims; few other categories of critically ill patients undergo such profound catabolism. 











important not least because burns patients can expect to be in hospital at least 1 day per 
percentage of body surface injured, usually translating to lengthy periods away from 
‘normal’ society, making reintegration very challenging indeed.  Further benefits are listed in 
Figure 3. 
 
Ventilator associated pneumonia is the most feared complication of endotracheal 
intubation, particularly in the burns patient, who are inherently more susceptible to 
infection in light of the overwhelming systemic inflammation and because normal defence 
mechanisms are bypassed (skin, gut, sinuses, orotracheal).  NIV has been shown to reduce 
the incidence of VAP, predominantly by reducing the period of ventilation and by 
maintaining intact airway protection mechanisms.  Shorter ICU stays are also independently 
related to improved survival, and translate into significant cost benefits for the health 
system. 18,19 
 
Success with NIV has traditionally only been achieved under certain circumstances.  The 
patient must be co-operative, able to protect his own airway, and have an intact cough 
reflex and adequate secretion clearance. Uncooperative patients may repeatedly remove 
their mask, ventilate out of sync with the ventilator or may not remove their mask in the 
event of vomiting, placing them at risk for aspiration.  Haemodynamic instability has been a 
relative contraindication for the use of NIV. Patients who cannot obtain an adequate seal are 
also excluded, as in a patient with gastrointestinal trauma or obstruction requiring 
nasogastric intubation and who are at risk for vomiting.  Aerophagia may also occur, 
particularly if the pressures used to ventilate are greater than 30mmHg, which would 
overcome the closing pressure of the lower oesophageal sphincter.  This is obviously 
particularly important in those with underlying gastrointestinal dysfunction or stasis, as is 












There is a paucity of literature describing the use of NIV in burn victims with or without 
inhalational injury, but its use ought to be considered in selected patients who meet these 
criteria for its use.  Inappropriate use of NIV in burn patients may be catastrophic.   This 
patient population is already at greater risk for haemodynamic instability and respiratory 
infection than other cohorts, and analgesic requirements may result in levels of sedation 
mitigating against the use of NIV.  Smailes was however able to reduce endotracheal re-
intubation to 7 of 30 burns patients with respiratory dysfunction after extubation.21   In 
another study, a 6-year review of the use of NIPPV as an adjunct to extubation, 104 
extubated paediatric burn patients were studied, only fifteen percent of whom required re-
intubation. Ten patients who experienced respiratory distress post-extubation received 
NIPPV support, of which four required re-intubation for worsening respiratory status, while 
six avoided re-intubation. 22 
 
More work has been done in trauma indications other than burns.  In one study by Linton, 
patients with blunt chest trauma were treated with either intubation and ventilation or NIV 
with CPAP. The two groups had similar levels of PEEP/CPAP, patient age, incidence of rib 
fractures, flail chest, and pulmonary contusion. The CPAP group had a smaller number of 
tracheostomies, less ICU days, and fewer complications. 23  In a further study, Hurst reviewed 
victims of blunt chest (rib fractures, pulmonary contusion, and flail chest) and penetrating 
chest injuries and long bone fractures.  CPAP was used in 33 alert patients with hypoxic 
respiratory failure. The mean duration of CPAP was 28 hours, and only two patients (6%) 
required intubation for failure of oxygenation but not ventilation.24 
 
Extrapolated to the intubated burns patient, earlier extubation and NIV application may 











may prove to be a useful adjunct allowing early extubation, providing bridging ventilatory 
support until normal respiration returns.  In the context of an acute major burn injury, it is 
rational to consider NIV (prophylactically) for the patient with high carbon monoxide blood 
levels, who is receiving significant fluid volumes, or who has history or examination features 
to suggest an inhalational injury, but who may not require intubation.  Clearly this 
represents a paradigm shift from the traditional teaching of early intubation in at-risk 
patients, but one must be cogniscent of the fact that these patients are in the high care 
setting and are awake, alert and cooperative on initiation of NIV.  The process of NIV would 
have been clearly discussed with them.  Any deterioration may warrant intubation and 
mechanical ventilation, in a controlled environment. 
 
On initiation of NIV, low levels of PEEP are applied, and once comfortable, the device is 
secured and set until the work of breathing (assessed by accessory muscle use, rate of 
respiration, tidal volume and patient comfort) is minimized.  Arterial blood gases, pulse 
oximetry, and end tidal CO2 should be monitored regularly.  
 
One of the major criticisms of NIV has been related to patient intolerance, particularly in the 
context of facial burns.   If the interface contributes to excessive pain, discomfort or 
claustrophobia for the patient, the benefits of NIV may be lost, and the patient more likely 
to require intubation and mechanical ventilation.   Optimal use has required a firm seal to 
maintain the pressure administered.  Certain devices have resulted in skin necrosis over the 
bridge of the nose or zygoma if worn for extended periods.  Pressure sores occur in up to 
10% of patients undergoing NIV; in patients with facial burns, this would be unacceptable.  
Duoderm (Convatec, USA) or a similar product may ameliorate these effects in some cases.   
 











purpose. 12, 25  Several studies have demonstrated its benefits, including improved comfort, 
ability to interact, while also reducing the likelihood of superadded cutaneous trauma where 
the equipment is secured, particularly in burns patients.  Criteria for use are similar to 
standard NIV principles.  While better tolerated, helmet NIV has been shown to be as 
effective as conventional face-mask NIV in reducing hospital stay, mortality, infectious 
morbidity (including pneumonia), as well as the requirement for invasive ventilation.  
Uncontrolled leaks are significantly less likely with helmets than with traditional facemask 
methods.  The only concern relating to helmet NIV has been its inability to maintain PCO2 
levels, probably as a result of C02 re-breathing.  Factors relating to patient-ventilator 
interaction may also need to be monitored more closely in patients using helmet NIV. 12, 25 
 
Key Major Recommendations 
 
1. Non-invasive ventilation is an important potential means of avoiding intubation in the 
major burns victim,  
 
2. NIV may also be utilised to maintain airway patency after extubation 
 
3. It is important that patients considered for NIV meet the criteria for its use, and be 
monitored appropriately. 
 
4. Transparent helmets have been designed and have shown to be as effective as traditional 
facemask interfaces; these may be more successfully applied in patients with facial burns.   
 
5. Prospective, randomized studies may better elucidate the role of NIV in burn patients 















1. Intubation (especially pre-
hospital/ emergency) 
Bypass glottis barrier; pooling, leak of and inability to 
clear secretions 
2. Cutaneous thermal injury Bacterial Reservoir; systemic inflammation; 
immunosuppression 
3. Prolonged ventilation Sustained micro-aspiration; secretions; reintubation 
4. Inhalational injury Direct injury; exudate formation; poor mucociliary 
clearance; reduced lung compliance; ARDS; 
prolonged ventilation; 
5. Transport out of ICU (e.g. 
theatre) 
Reintubation; bacterial translocation 
6. Blood transfusions Immunosuppression 
Figure 1.  Factors predisposing the burns patient to pneumonia in ICU  
 
Preventing VAP in Burns patients 
1. Reduce the duration of ventilation 
2. Postpyloric feeding 
3. Chlorhexidine mouth wash 
4. Reduce transfusions 
5. Head elevation 
6. Selective decontamination of the GIT 
7. Staff factors – hand hygiene and barrier 
nursing 
8. Silver endotracheal tubes and continuous 
aspiration 
9. Non-invasive ventilation as adjunct to 
extubation 




























Potential benefits of NIV in Burns 
1. Improved communication 
2. Better oral intake and gut function 
3. Oral hygiene 
4. Avoid orotracheal injury and barotrauma 
5. Reduced respiratory tract infections 
6. Maintain protective mechanisms  
7. Less sinusitis 
8. Shorter ICU and hospital stays 
9. Improved speech and swallowing after 
extubation 
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